Yosemite develops novel oncology therapeutics by leveraging proprietary AI-driven drug discovery platforms. The company engineers targeted protein degraders and advanced formulations to create more effective treatment options for cancer patients.
Funding
Funding not disclosed
Founders
Product
Problem
Cancer remains a significant challenge, often progressing to a lethal stage despite current treatment modalities. This necessitates the development of novel therapeutic strategies to improve patient prognoses and quality of life.
Solution
Yosemite is focused on advancing oncology through the discovery and development of innovative therapeutic platforms. Our approach leverages proprietary drug discovery engines to identify and engineer novel molecular entities with enhanced efficacy and safety profiles. We are committed to translating these scientific advancements into clinical applications that can transform cancer from a life-threatening diagnosis into a manageable chronic condition. By targeting key oncogenic pathways and employing advanced delivery systems, we aim to provide patients with more effective treatment options and improved long-term outcomes.
Target Audience
Our primary target audience includes pharmaceutical companies seeking to license novel oncology assets and clinical-stage biotechnology firms looking to expand their therapeutic portfolios.
Features
- Proprietary small molecule discovery platform utilizing AI-driven hit identification and lead optimization.
- Development of targeted protein degraders (PROTACs) for novel therapeutic mechanisms.
- Advanced formulation technologies for enhanced drug delivery and bioavailability.
- Preclinical pipeline targeting key oncogenic drivers in solid tumors and hematological malignancies.
- Robust intellectual property portfolio covering novel chemical entities and therapeutic applications.